CD274 and non-small cell lung carcinoma: As the use of ICIs also in first-line therapy is rapidly changing the treatment scenario for advanced NSCLC, robust predictive biomarkers might prove critical for therapeutic decisions, especially in the case of reliable negative predictive factors, which may potentially allow selection of those patients who do not benefit from the use of an ICI in addition to or in place of platinum-based chemotherapy, irrespective of PD-L1 expression.